PMC:7445716 / 43983-44415 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T227","span":{"begin":114,"end":119},"obj":"Body_part"},{"id":"T228","span":{"begin":140,"end":152},"obj":"Body_part"},{"id":"T229","span":{"begin":300,"end":303},"obj":"Body_part"},{"id":"T230","span":{"begin":337,"end":344},"obj":"Body_part"},{"id":"T231","span":{"begin":364,"end":368},"obj":"Body_part"}],"attributes":[{"id":"A227","pred":"fma_id","subj":"T227","obj":"http://purl.org/sig/ont/fma/fma9576"},{"id":"A228","pred":"fma_id","subj":"T228","obj":"http://purl.org/sig/ont/fma/fma82816"},{"id":"A229","pred":"fma_id","subj":"T229","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A230","pred":"fma_id","subj":"T230","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A231","pred":"fma_id","subj":"T231","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"ir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT NA Negative anti-gangliosides antibodies; negative screening for Campylobacter jejuni, Mycoplasma pneumoniae, Salmonella enterica, CMV, EBV, HSV1-2, VZV, Influenza virus A \u0026 B, HIV, and hepatitis E Increased total protein (1.66 g/L), normal cell count Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) + mechanica"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T121","span":{"begin":114,"end":119},"obj":"Body_part"}],"attributes":[{"id":"A121","pred":"uberon_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"}],"text":"ir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT NA Negative anti-gangliosides antibodies; negative screening for Campylobacter jejuni, Mycoplasma pneumoniae, Salmonella enterica, CMV, EBV, HSV1-2, VZV, Influenza virus A \u0026 B, HIV, and hepatitis E Increased total protein (1.66 g/L), normal cell count Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) + mechanica"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T467","span":{"begin":29,"end":31},"obj":"Disease"},{"id":"T468","span":{"begin":210,"end":231},"obj":"Disease"},{"id":"T469","span":{"begin":277,"end":286},"obj":"Disease"},{"id":"T470","span":{"begin":309,"end":320},"obj":"Disease"},{"id":"T471","span":{"begin":309,"end":318},"obj":"Disease"},{"id":"T472","span":{"begin":389,"end":393},"obj":"Disease"}],"attributes":[{"id":"A467","pred":"mondo_id","subj":"T467","obj":"http://purl.obolibrary.org/obo/MONDO_0007886"},{"id":"A468","pred":"mondo_id","subj":"T468","obj":"http://purl.obolibrary.org/obo/MONDO_0005867"},{"id":"A469","pred":"mondo_id","subj":"T469","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A470","pred":"mondo_id","subj":"T470","obj":"http://purl.obolibrary.org/obo/MONDO_0005788"},{"id":"A471","pred":"mondo_id","subj":"T471","obj":"http://purl.obolibrary.org/obo/MONDO_0002251"},{"id":"A472","pred":"mondo_id","subj":"T472","obj":"http://purl.obolibrary.org/obo/MONDO_0020347"}],"text":"ir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT NA Negative anti-gangliosides antibodies; negative screening for Campylobacter jejuni, Mycoplasma pneumoniae, Salmonella enterica, CMV, EBV, HSV1-2, VZV, Influenza virus A \u0026 B, HIV, and hepatitis E Increased total protein (1.66 g/L), normal cell count Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) + mechanica"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T275","span":{"begin":101,"end":103},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T276","span":{"begin":114,"end":119},"obj":"http://www.ebi.ac.uk/efo/EFO_0000965"},{"id":"T277","span":{"begin":287,"end":292},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T278","span":{"begin":293,"end":294},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T279","span":{"begin":297,"end":298},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T280","span":{"begin":364,"end":368},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"ir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT NA Negative anti-gangliosides antibodies; negative screening for Campylobacter jejuni, Mycoplasma pneumoniae, Salmonella enterica, CMV, EBV, HSV1-2, VZV, Influenza virus A \u0026 B, HIV, and hepatitis E Increased total protein (1.66 g/L), normal cell count Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) + mechanica"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T241","span":{"begin":4,"end":13},"obj":"Chemical"},{"id":"T242","span":{"begin":36,"end":38},"obj":"Chemical"},{"id":"T243","span":{"begin":123,"end":125},"obj":"Chemical"},{"id":"T244","span":{"begin":140,"end":152},"obj":"Chemical"},{"id":"T245","span":{"begin":337,"end":344},"obj":"Chemical"},{"id":"T246","span":{"begin":394,"end":396},"obj":"Chemical"}],"attributes":[{"id":"A241","pred":"chebi_id","subj":"T241","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A242","pred":"chebi_id","subj":"T242","obj":"http://purl.obolibrary.org/obo/CHEBI_73531"},{"id":"A243","pred":"chebi_id","subj":"T243","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A244","pred":"chebi_id","subj":"T244","obj":"http://purl.obolibrary.org/obo/CHEBI_28892"},{"id":"A245","pred":"chebi_id","subj":"T245","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A246","pred":"chebi_id","subj":"T246","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"}],"text":"ir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT NA Negative anti-gangliosides antibodies; negative screening for Campylobacter jejuni, Mycoplasma pneumoniae, Salmonella enterica, CMV, EBV, HSV1-2, VZV, Influenza virus A \u0026 B, HIV, and hepatitis E Increased total protein (1.66 g/L), normal cell count Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) + mechanica"}

{"project":"LitCovid-PubTator","denotations":[{"id":"727","span":{"begin":187,"end":207},"obj":"Species"},{"id":"728","span":{"begin":209,"end":230},"obj":"Species"},{"id":"729","span":{"begin":232,"end":251},"obj":"Species"},{"id":"730","span":{"begin":263,"end":267},"obj":"Species"},{"id":"731","span":{"begin":276,"end":291},"obj":"Species"},{"id":"811","span":{"begin":258,"end":261},"obj":"Species"},{"id":"884","span":{"begin":35,"end":46},"obj":"Disease"},{"id":"885","span":{"begin":63,"end":91},"obj":"Disease"},{"id":"886","span":{"begin":308,"end":319},"obj":"Disease"},{"id":"887","span":{"begin":374,"end":392},"obj":"Disease"}],"attributes":[{"id":"A727","pred":"tao:has_database_id","subj":"727","obj":"Tax:197"},{"id":"A728","pred":"tao:has_database_id","subj":"728","obj":"Tax:2104"},{"id":"A729","pred":"tao:has_database_id","subj":"729","obj":"Tax:28901"},{"id":"A730","pred":"tao:has_database_id","subj":"730","obj":"Tax:10298"},{"id":"A731","pred":"tao:has_database_id","subj":"731","obj":"Tax:11308"},{"id":"A811","pred":"tao:has_database_id","subj":"811","obj":"Tax:10376"},{"id":"A884","pred":"tao:has_database_id","subj":"884","obj":"MESH:D018908"},{"id":"A885","pred":"tao:has_database_id","subj":"885","obj":"MESH:C531747"},{"id":"A886","pred":"tao:has_database_id","subj":"886","obj":"MESH:D016751"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT NA Negative anti-gangliosides antibodies; negative screening for Campylobacter jejuni, Mycoplasma pneumoniae, Salmonella enterica, CMV, EBV, HSV1-2, VZV, Influenza virus A \u0026 B, HIV, and hepatitis E Increased total protein (1.66 g/L), normal cell count Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) + mechanica"}

{"project":"LitCovid-sentences","denotations":[{"id":"T227","span":{"begin":80,"end":388},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT NA Negative anti-gangliosides antibodies; negative screening for Campylobacter jejuni, Mycoplasma pneumoniae, Salmonella enterica, CMV, EBV, HSV1-2, VZV, Influenza virus A \u0026 B, HIV, and hepatitis E Increased total protein (1.66 g/L), normal cell count Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) + mechanica"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T645","span":{"begin":64,"end":79},"obj":"Phenotype"},{"id":"T646","span":{"begin":221,"end":231},"obj":"Phenotype"},{"id":"T647","span":{"begin":309,"end":318},"obj":"Phenotype"},{"id":"T648","span":{"begin":375,"end":388},"obj":"Phenotype"}],"attributes":[{"id":"A645","pred":"hp_id","subj":"T645","obj":"http://purl.obolibrary.org/obo/HP_0001349"},{"id":"A646","pred":"hp_id","subj":"T646","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A647","pred":"hp_id","subj":"T647","obj":"http://purl.obolibrary.org/obo/HP_0012115"},{"id":"A648","pred":"hp_id","subj":"T648","obj":"http://purl.obolibrary.org/obo/HP_0011096"}],"text":"ir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT NA Negative anti-gangliosides antibodies; negative screening for Campylobacter jejuni, Mycoplasma pneumoniae, Salmonella enterica, CMV, EBV, HSV1-2, VZV, Influenza virus A \u0026 B, HIV, and hepatitis E Increased total protein (1.66 g/L), normal cell count Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) + mechanica"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T436","span":{"begin":64,"end":70},"obj":"UBERON:0001456"},{"id":"T437","span":{"begin":114,"end":119},"obj":"UBERON:0001443"},{"id":"T438","span":{"begin":140,"end":152},"obj":"CHEBI:16856;CHEBI:16856"},{"id":"T439","span":{"begin":153,"end":163},"obj":"GO:0042571"},{"id":"T440","span":{"begin":188,"end":201},"obj":"NCBITaxon:197"},{"id":"T441","span":{"begin":202,"end":208},"obj":"NCBITaxon:6142"},{"id":"T442","span":{"begin":210,"end":231},"obj":"NCBITaxon:2104"},{"id":"T443","span":{"begin":233,"end":252},"obj":"NCBITaxon:562"},{"id":"T444","span":{"begin":254,"end":257},"obj":"NCBITaxon:10358"},{"id":"T445","span":{"begin":259,"end":262},"obj":"NCBITaxon:10376"},{"id":"T446","span":{"begin":264,"end":268},"obj":"NCBITaxon:10298;PR:Q02887"},{"id":"T447","span":{"begin":277,"end":286},"obj":"NCBITaxon:7719"},{"id":"T448","span":{"begin":287,"end":292},"obj":"NCBITaxon:10239"}],"text":"ir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT NA Negative anti-gangliosides antibodies; negative screening for Campylobacter jejuni, Mycoplasma pneumoniae, Salmonella enterica, CMV, EBV, HSV1-2, VZV, Influenza virus A \u0026 B, HIV, and hepatitis E Increased total protein (1.66 g/L), normal cell count Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) + mechanica"}

{"project":"2_test","denotations":[{"id":"32840686-32334841-63205757","span":{"begin":100,"end":102},"obj":"32334841"}],"text":"ir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT NA Negative anti-gangliosides antibodies; negative screening for Campylobacter jejuni, Mycoplasma pneumoniae, Salmonella enterica, CMV, EBV, HSV1-2, VZV, Influenza virus A \u0026 B, HIV, and hepatitis E Increased total protein (1.66 g/L), normal cell count Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) + mechanica"}